DESIGN OF EXTENDED RELEASE MATRIX TABLET OF TRAMADOL HYDROCHLORIDE USING COMBINATION OF HYDROPHOBIC AND HYDROPHILIC POLYMER
Abstract
The aim of design of oral extended drug delivery system is to achieve a prolonged therapeutic effect by continuously releasing medicament over an extended period of time after administration of a single dose. An attempt was made to formulate Tramadol Extended Release (ER) matrix tablet using combination of hydrophobic and hydrophilic polymer consisting of ethyl cellulose, HPMC K15M, carbopol, and xanthan gum. The polymeric concentration of hydrophobic and hydrophilic polymer was optimized and was found that drug to polymeric ratio (hydrophobic and hydrophilic) of 1:0.75:0.75 was appropriate for the formulation of Tramadol ER tablet. The concentration of hydrophobic polymer was kept constant were as the combination of hydrophilic polymer was attempted and combined to hydrophobic polymer to retard the drug release for 24-hour from the matrix tablet. A total of nine formulations (F1-F9) of Tramadol matrix tablet, with different concentration of hydrophobic and hydrophilic polymer were used with other excipients. The tablets were compressed by direct compression method after subjecting the blend to blend physical parameters studies like studies like angle of repose, bulk density, tapped density, Carr’s index. The results obtained were satisfactory. Post compression parameters like hardness, weight variation, friability, drug content analysis and in-vitro release profiles of drug from all the formulations could be best expressed by Higuchi’s equation, as the plots showed high linearity (R2: 0.942-0.995). To confirm the diffusion mechanism, the data were fit into Korsmeyer equation. The formulations F-1 to F-6 showed good linearity (R2: 0.961 to 0.993), which indicate the mechanism is diffusion coupled with erosion.
Keywords:
Sustained drug delivery system, matrix tablet, hydrophobic and hydrophilic polymer, pharmacokinetic and pharmacodynamics, release kinetics.DOI
https://doi.org/10.25004/IJPSDR.2017.090502References
2. Remingtons, Pharmaceutical Sciences. 16th Edition, Mack Publishing Company, 1980, pp. 1677-1683.
3. Yie W. Chein. Novel drug delivery Systems, 3nd ed., Marcel Dekker, Inc., 2001, pp. 53.
4. Aulton ME. Pharmaceutics-The Sciences of Dosages form design, 4th ed., Edition international student Edition, Churchill Livingston, pp. 129-191.
5. Bramankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics, a treatise, Vallabh Prakashan, 2005 pp. 305-371.
6. Jantzen GM, Robinson JR. Sustained and Controlled Release Drug Delivery Systems, Modern Pharmaceutics, Fourth Edition Edited by Gilbert S. Banker and Christopher T. Rhodes CRC Press 2002: 581-590.
7. United States Pharmacopoeia. 25th Edn., The United States Pharmacopoeial convention, Inc., Rockville, 2002, pp. 1821-1824.
8. Umesh VB, oral rate controlled drug administration manufuring chemist, 1988, pp. 14-217.
9. Woolf CJ, Mannion RJ. Neuropathic pain: etiology, symptoms, mechanisms, and management. Lancet. 1999; 353:1959-64.
10. Loeser JD, Melzack R. Pain: an overview. The Lancet. 1999 May 8;353(9164):1607-9.
11. Kasper DL, Braunwald E, Fauci AS et al, (Eds.) Harrison's principles of internal medicine. 16th edition. McGraw-Hill, New York; 2005, pp.145-150.
12. Dhasmana KM, Lachmann B. Therapeutic application of tramadol in the treatment of pain compared to other opiates. Indian Journal of Pharmacology. 1990 Oct 1;22(4):184-191.
13. Schug SA. The role of tramadol in current treatment strategies for musculoskeletal pain. Therapeutics and clinical risk management. 2007 Oct;3(5):717-723.
14. Gana TJ, Pascual ML, Fleming RR, Schein JR, Janagap CC, Xiang J, Vorsanger GJ, 023 Study Group. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Current medical research and opinion. 2006 Jul 1;22(7):1391-401.
15. Zhang ZY, Ping QN, Xiao B. Microencapsulation and characterization of tramadol–resin complexes. Journal of Controlled release. 2000 May 15;66(2):107-13.
16. Espinoza-Ramos R, Villafuerte-Robles L. Influence of admixed lactose on pelanserin hydrochloride release from hydroxypropyl methylcellulose matrix tablets. Pharmaceutica Acta Helvetiae. 1999 Dec 31;74(1):65-71.
17. Ryoichi M, Honda R, Takahashi Y. Development of oral controlled release preparations, a PVA swelling controlled release system (SCRS). II. Vitro and in Vivo Evaluation. J. Control. Rel. 2000;68:115-20.
18. Munday DL, Cox PJ. Compressed xanthan and karaya gum matrices: hydration, erosion and drug release mechanisms. International journal of pharmaceutics. 2000 Aug 1;203(1):179-92.
19. Qiu Y, Flood K, Marsh K, Carroll S, Trivedi J, Arneric SP, Krill SL. Design of sustained-release matrix systems for a highly water-soluble compound, ABT-089. International journal of pharmaceutics. 1997 Nov 14;157(1):43-52.
20. Talukdar MM, Van den Mooter G, Augustijns P, Tjandra-Maga T, Verbeke N, Kinget R. In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation. International journal of pharmaceutics. 1998 Jun 30;169(1):105-13.
21. Muramatsu M, Kanada K, Nishida A, Ouchi K, Saito N, Yoshida M, Shimoaka A, Ozeki T, Yuasa H, Kanaya Y. Application of Carbopol® to controlled release preparations I. Carbopol® as a novel coating material. International journal of pharmaceutics. 2000 Apr 10;199(1):77-83.
22. Steendam R, Lerk CF. Poly (DL-lactic acid) as a direct compression excipient in controlled release tablets: part I. Compaction behaviour and release characteristics of poly (DL-lactic acid) matrix tablets. International journal of pharmaceutics. 1998 Nov 26;175(1):33-46.
23. Mandal U, Gowda V, Ghosh A, Selvan S, Solomon S, Pal TK. Formulation and optimization of sustained release matrix tablet of metformin HCl 500 mg using response surface methodology. Yakugaku zasshi. 2007 Jun 1;127(8):1281-90.
24. Sriwongjanya M, Bodmeier R. Effect of ion exchange resins on the drug release from matrix tablets. European journal of pharmaceutics and biopharmaceutics. 1998 Nov 1;46(3):321-7.
25. Varshosaz J, Tavakoli N, Kheirolahi F. Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride. AAPS PharmSciTech. 2006 Mar 1;7(1):E168-74.
26. Emami J, Tavakoli N, Movahedian A. Formulation of sustained-release lithium carbonate matrix tablets: influence of hydrophilic materials on the release rate and in vitro-in vivo evaluation. J Pharm Pharm Sci. 2004 Nov 15;7(3):338-44.
Published
Abstract Display: 469 
PDF Downloads: 441 
